Jiaojiao Sun
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Jiaojiao Sun has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Hong Yu
Department of Human Anatomy and Histoembryology, School of Basic Medical Sciences, Southwest Medical University, Luzhou 646000, Sichuan, China
2 shared publications - Qiuhong Li
School of Basic Medical Sciences, Southwest Medical University, Luzhou, China
2 shared publications - Shengbiao Li
Department of Medical Cell Biology and Genetics, School of Basic Medical Sciences, Key Laboratory of Medical Electrophysiology, Ministry of Education, Institute of Cardiovascular Research, Southwest Medical University, Luzhou, China
2 shared publications - Yuping He
Department of Histology and Embryology, School of Basic Medical Sciences, Southwest Medical University, Luzhou 646000, Sichuan, China
2 shared publications - Guangyi Liu
Department of Histology and Embryology, School of Basic Medical Sciences, Southwest Medical University, Luzhou 646000, Sichuan, China
1 shared publication - Jiaxin Wang
Department of Histology and Embryology, School of Basic Medical Sciences, Southwest Medical University, Luzhou, 646000, Sichuan, China, swmu.edu.cn
1 shared publication
Latest Publications
- Open Access
- 1 January 2026
- Published by Wiley in Neural Plasticity
- Vol. 2026 (1)
Berberine Alleviates Lipopolysaccharide‐Induced Impairments in Neuroplasticity and Spatial Memory by Modulating Microglial Polarization via MAPK Signaling Inhibition
Neuroinflammation‐induced cognitive impairment is characterized by a continued decline in memory, executive functioning, and information‐processing abilities. Although berberine (BBR) exhibits anti‐inflammatory and neuroprotective properties, its ability to mitigate cognitive deficits by regulating microglial‐mediated neuroinflammation remains incompletely understood. To investigate the potential of BBR in mitigating microglial‐mediated neuroinflammation and its detrimental effects on neuroplasticity and spatial memory, a mouse model was established through intrahippocampal microinjection of lipopolysaccharide (LPS). The results showed that BBR pretreatment significantly improved cognitive performance, suppressed microglial activation, reduced hippocampal neuronal damage, and increased the density of functional dendritic spines. Mechanistic analysis revealed that BBR treatment inhibited the phosphorylation of key proteins in the MAPK signaling pathway within microglia. These findings suggest that BBR is a promising therapeutic agent for mitigating neuroinflammation‐induced cognitive impairment and provide significant evidence for its potential application in treating inflammation‐related cognitive deficits.
- 1 January 2026
- Published by Wiley in Neural Plasticity
- Vol. 2026 (1)
Open AccessBerberine Alleviates Lipopolysaccharide‐Induced Impairments in Neuroplasticity and Spatial Memory by Modulating Microglial Polarization via MAPK Signaling Inhibition
Neuroinflammation‐induced cognitive impairment is characterized by a continued decline in memory, executive functioning, and information‐processing abilities. Although berberine (BBR) exhibits anti‐inflammatory and neuroprotective properties, its ability to mitigate cognitive deficits by regulating microglial‐mediated neuroinflammation remains incompletely understood. To investigate the potential of BBR in mitigating microglial‐mediated neuroinflammation and its detrimental effects on neuroplasticity and spatial memory, a mouse model was established through intrahippocampal microinjection of lipopolysaccharide (LPS). The results showed that BBR pretreatment significantly improved cognitive performance, suppressed microglial activation, reduced hippocampal neuronal damage, and increased the density of functional dendritic spines. Mechanistic analysis revealed that BBR treatment inhibited the phosphorylation of key proteins in the MAPK signaling pathway within microglia. These findings suggest that BBR is a promising therapeutic agent for mitigating neuroinflammation‐induced cognitive impairment and provide significant evidence for its potential application in treating inflammation‐related cognitive deficits.
- Open Access
- 16 December 2021
- Published by Wiley in Evidence-Based Complementary and Alternative Medicine
- Vol. 2021, 1-12
A System Bioinformatics Approach Predicts the Molecular Mechanism Underlying the Course of Action of Radix Salviae Reverses GBM Effects
Objective. This study used in vitro techniques to investigate the therapeutic effect of Radix Salviae on human glioblastoma and decode its underlying molecular mechanism. Methods. The active components and targets of the Radix Salviae were identified from the Traditional Chinese Medicine Systems Pharmacology Database (TCMSP). The targets of human glioblastoma were obtained from the GeneCards Database. The Radix Salviae-mediated antiglioblastoma was evaluated by Gene Ontology (GO) analyses and Kyoto Encyclopedia of Genes and Genomes pathway enrichment analyses. Finally, mechanism of action of Radix Salviae against human glioblastoma was deduced by molecular docking and experiments. Results. We screened 66 active ingredients and 45 targets of the Radix Salviae. The enrichment analysis based on the targets mentioned above suggested a possible role in protein phosphorylation, cell transcription, apoptosis, and inflammatory factor signaling pathways. Further study demonstrated that cryptotanshinone, an essential component of Radix Salviae, played a significant role in killing human glioblastoma cells and protecting the body by inhibiting the AKT, IKB, and STAT3 signaling pathways. Conclusions. Radix Salviae could inhibit the proliferation and invasion of human glioblastoma by regulating STAT3, Akt, and IKB signaling pathways. Radix Salviae has potential therapeutic value in the future for human glioblastoma.
- 16 December 2021
- Published by Wiley in Evidence-Based Complementary and Alternative Medicine
- Vol. 2021, 1-12
Open AccessA System Bioinformatics Approach Predicts the Molecular Mechanism Underlying the Course of Action of Radix Salviae Reverses GBM Effects
Objective. This study used in vitro techniques to investigate the therapeutic effect of Radix Salviae on human glioblastoma and decode its underlying molecular mechanism. Methods. The active components and targets of the Radix Salviae were identified from the Traditional Chinese Medicine Systems Pharmacology Database (TCMSP). The targets of human glioblastoma were obtained from the GeneCards Database. The Radix Salviae-mediated antiglioblastoma was evaluated by Gene Ontology (GO) analyses and Kyoto Encyclopedia of Genes and Genomes pathway enrichment analyses. Finally, mechanism of action of Radix Salviae against human glioblastoma was deduced by molecular docking and experiments. Results. We screened 66 active ingredients and 45 targets of the Radix Salviae. The enrichment analysis based on the targets mentioned above suggested a possible role in protein phosphorylation, cell transcription, apoptosis, and inflammatory factor signaling pathways. Further study demonstrated that cryptotanshinone, an essential component of Radix Salviae, played a significant role in killing human glioblastoma cells and protecting the body by inhibiting the AKT, IKB, and STAT3 signaling pathways. Conclusions. Radix Salviae could inhibit the proliferation and invasion of human glioblastoma by regulating STAT3, Akt, and IKB signaling pathways. Radix Salviae has potential therapeutic value in the future for human glioblastoma.
- Open Access
- 1 January 2021
- Published by Wiley in Oxidative Medicine and Cellular Longevity
- Vol. 2021 (1) , 2915019
RSL3 Drives Ferroptosis through NF‐κB Pathway Activation and GPX4 Depletion in Glioblastoma
Glioblastoma, the most aggressive form of malignant glioma, is very difficult to treat because of its aggressively invasive nature and high recurrence rates. RAS‐selective lethal 3 (RSL3), a well‐known inhibitor of glutathione peroxidase 4 (GPX4), could effectively induce oxidative cell death in glioblastoma cells through ferroptosis, and several signaling pathways are involved in this process. However, the role of the nuclear factor kappa‐B (NF‐κB) pathway in glioblastoma cell ferroptosis has not yet been investigated. Therefore, we aimed to clarify the underlying mechanism of the NF‐κB pathway in RSL3‐induced ferroptosis in glioblastoma cells. We found that RSL3 led to an increase in lipid ROS concentration and downregulation of ferroptosis‐related proteins such as GPX4, ATF4, and SLC7A11 (xCT) in glioblastoma cells. Additionally, the NF‐κB pathway was activated by RSL3, and its inhibition by BAY 11‐7082 could alleviate ferroptosis. The murine xenograft tumor model indicated that NF‐κB pathway inhibition could mitigate the antitumor effects of RSL3 in vivo. Furthermore, we found that GPX4 knockdown could not effectively induce ferroptosis. However, NF‐κB pathway activation coupled with GPX4 silencing induced ferroptosis. Additionally, ATF4 and xCT expression might be regulated by the NF‐κB pathway. Collectively, our results revealed that the NF‐κB pathway plays a novel role in RSL3‐induced ferroptosis in glioblastoma cells and provides a new therapeutic strategy for glioblastoma treatment.
- 1 January 2021
- Published by Wiley in Oxidative Medicine and Cellular Longevity
- Vol. 2021 (1) , 2915019
Open AccessRSL3 Drives Ferroptosis through NF‐κB Pathway Activation and GPX4 Depletion in Glioblastoma
Glioblastoma, the most aggressive form of malignant glioma, is very difficult to treat because of its aggressively invasive nature and high recurrence rates. RAS‐selective lethal 3 (RSL3), a well‐known inhibitor of glutathione peroxidase 4 (GPX4), could effectively induce oxidative cell death in glioblastoma cells through ferroptosis, and several signaling pathways are involved in this process. However, the role of the nuclear factor kappa‐B (NF‐κB) pathway in glioblastoma cell ferroptosis has not yet been investigated. Therefore, we aimed to clarify the underlying mechanism of the NF‐κB pathway in RSL3‐induced ferroptosis in glioblastoma cells. We found that RSL3 led to an increase in lipid ROS concentration and downregulation of ferroptosis‐related proteins such as GPX4, ATF4, and SLC7A11 (xCT) in glioblastoma cells. Additionally, the NF‐κB pathway was activated by RSL3, and its inhibition by BAY 11‐7082 could alleviate ferroptosis. The murine xenograft tumor model indicated that NF‐κB pathway inhibition could mitigate the antitumor effects of RSL3 in vivo. Furthermore, we found that GPX4 knockdown could not effectively induce ferroptosis. However, NF‐κB pathway activation coupled with GPX4 silencing induced ferroptosis. Additionally, ATF4 and xCT expression might be regulated by the NF‐κB pathway. Collectively, our results revealed that the NF‐κB pathway plays a novel role in RSL3‐induced ferroptosis in glioblastoma cells and provides a new therapeutic strategy for glioblastoma treatment.